Clinical Trials Logo

Cognitive Symptom clinical trials

View clinical trials related to Cognitive Symptom.

Filter by:

NCT ID: NCT03246269 Completed - Dementia Clinical Trials

Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)

MoCA-Norm
Start date: December 2016
Phase:
Study type: Observational

This observational cohort study in healthy volunteers establishes normative data for the German version of the Montreal Cognitive Assessment (MoCA) and investigates the possible impacts of demographics on the MoCA total score.

NCT ID: NCT03232697 Completed - Cognitive Symptom Clinical Trials

French Language Validation of the 5-minutes Montreal Cognitive Assessment (MoCA)

MoCATEL
Start date: July 12, 2017
Phase: N/A
Study type: Interventional

The aim of the study is to validate a french version of the 5 minutes version of the Montreal Cognitive Assessment as compared to the french full version of this test.

NCT ID: NCT03227653 Completed - Clinical trials for Medication Adherence

Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV

Start date: June 19, 2017
Phase:
Study type: Observational

Efavirenz is among the preferred antiretroviral drugs for HIV-infected children. Increasing evidence shows that central nervous system side-effects in adults are more common than previously thought. Still, reliable data in children are lacking. As HIV-infected children nowadays have a prospect of reaching adulthood, there is an urgent need to identify potential long-term central nervous system side-effects, interfering with neurodevelopment and psychosocial maturation. Using validated tools, we assessed (1) competence (social/activities/school) and psychopathology (internalizing/externalizing problems), (2) cognitive performance (intelligence and working memory), and (3) adherence in Tanzanian children on an efavirenz or non-efavirenz based regimen In this cross-sectional observational study the investigators will examine neuropsychiatric and neurocognitive functioning in 126 children (aged 6-11 years) on long-term combination antiretroviral therapy (cART) with or without efavirenz.